<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Secondary prevention of CVD | Management | Antiplatelet treatment | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers when to prescribe antiplatelet drugs in a person who has had a prior cardiovascular event (for example, myocardial infarction or stroke), which antiplatelet drug to prescribe, the management of gastrointestinal adverse effects caused by antiplatelet drugs and high blood pressure."/><meta data-react-helmet="true" property="og:description" content="Covers when to prescribe antiplatelet drugs in a person who has had a prior cardiovascular event (for example, myocardial infarction or stroke), which antiplatelet drug to prescribe, the management of gastrointestinal adverse effects caused by antiplatelet drugs and high blood pressure."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Secondary prevention of CVD | Management | Antiplatelet treatment | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Antiplatelet treatment</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Secondary prevention of CVD</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/antiplatelet-treatment/","name":"Antiplatelet treatment"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/antiplatelet-treatment/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Secondary prevention of CVD"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Antiplatelet treatment: </span><span>Scenario: Antiplatelet treatment for secondary prevention of cardiovascular disease (CVD)</span></h1><p class="page-header__lead"><span>Last revised in August 2020</span></p></div><p class="visually-hidden">Covers when to prescribe antiplatelet drugs in a person who has had a prior cardiovascular event (for example, myocardial infarction or stroke), which antiplatelet drug to prescribe, the management of gastrointestinal adverse effects caused by antiplatelet drugs and high blood pressure.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Antiplatelet treatment chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Primary prevention of CVD"><a aria-current="false" href="../primary-prevention-of-cvd/index.html"><span class="stacked-nav__content-wrapper">Scenario: Primary prevention of CVD</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Secondary prevention of CVD"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Secondary prevention of CVD</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Prescribing information"><a aria-current="false" href="../../prescribing-information/index.html"><span class="stacked-nav__content-wrapper">Prescribing information</span></a></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#when-to-prescribe-antiplatelet-treatment">When to prescribe antiplatelet treatment</a><ol aria-label="Sections within When to prescribe antiplatelet treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-a0b">Basis for recommendation</a></li></ol></li><li><a href="index.html#which-antiplatelet-treatment">Which antiplatelet treatment</a><ol aria-label="Sections within Which antiplatelet treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-938">Basis for recommendation</a></li></ol></li><li><a href="index.html#preventing-dyspepsia">Preventing dyspepsia</a><ol aria-label="Sections within Preventing dyspepsia" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#high-risk-of-gi-adverse-effects">High risk of GI adverse effects</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-1c6">Basis for recommendation</a></li></ol></li><li><a href="index.html#managing-antiplatelet-induced-dyspepsia">Managing antiplatelet-induced dyspepsia</a><ol aria-label="Sections within Managing antiplatelet-induced dyspepsia" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-78f">Basis for recommendation</a></li></ol></li><li><a href="index.html#switching-antiplatelets">Switching antiplatelets</a><ol aria-label="Sections within Switching antiplatelets" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-9ff">Basis for recommendation</a></li></ol></li><li><a href="index.html#surgery-dental-treatment">Surgery and dental treatment</a><ol aria-label="Sections within Surgery and dental treatment" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-7b8">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="secondary-prevention-of-cvd" class="ChapterBody-module--wrapper--2HCfk "><h2 id="secondary-prevention-of-cvd" class="visually-hidden">Scenario: Antiplatelet treatment for secondary prevention of cardiovascular disease (CVD)</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c81bf9ec-43d5-48c7-89d7-a7810088fd62 --><!-- begin field 657e13d0-569e-4395-b40c-acbc01567736 --><p>From age 16 years onwards.</p><!-- end field 657e13d0-569e-4395-b40c-acbc01567736 --><!-- end item c81bf9ec-43d5-48c7-89d7-a7810088fd62 --></div><section aria-labelledby="when-to-prescribe-antiplatelet-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="when-to-prescribe-antiplatelet-treatment">When should antiplatelet treatment be prescribed for secondary prevention of cardiovascular disease?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 057f77b6-177d-4761-b392-a7810088fe7c --><!-- begin field f5682592-6b6e-41d5-a783-a7810088fe7c --><ul><li>Antiplatelet treatment should be prescribed for the secondary prevention of cardiovascular events in people with:<ul><li>Acute coronary syndrome (ACS).</li><li>Angina.</li><li>Atrial fibrillation (AF)  in these peopleanticoagulants are more usuallyprescribed.</li><li>Peripheral arterial disease (PAD).</li></ul></li><li>Antiplatelet treatment should also beprescribed for the secondary prevention of cardiovascular events in people after:<ul><li>Myocardial infarction (MI).</li><li>Stent implantation.</li><li>Stroke or transient ischaemic attack (TIA).</li></ul></li><li>For further information, see the CKS topics on <a class="topic-reference external-reference" href="../../../angina/index.html">Angina</a>,<a class="topic-reference external-reference" href="../../../mi-secondary-prevention/index.html">MI - secondary prevention</a>,<a class="topic-reference external-reference" href="../../../atrial-fibrillation/index.html">Atrial fibrillation</a>, and<a class="topic-reference external-reference" href="../../../stroke-tia/index.html">Stroke and TIA</a>.</li></ul><!-- end field f5682592-6b6e-41d5-a783-a7810088fe7c --><!-- end item 057f77b6-177d-4761-b392-a7810088fe7c --></div><section aria-labelledby="basis-for-recommendation-a0b" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-a0b">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a0b8f2ff-1ff4-4864-8a45-a7810088fe81 --><!-- begin field bb84f230-c7f7-470a-ada3-a7810088fe81 --><p>These recommendations are based onthe National Institute for Health and Care Excellence (NICE) guidelines<em>Stable angina: management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016a</a>], <em>Unstable angina and NSTEMI: early management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013a</a>],<em>Transient ischaemic attack: clopidogrel</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013c</a>],<em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013b</a>],the Scottish Intercollegiate Guidelines Network (SIGN) guidelines<em>Antithrombotics: indications and management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>]and <em>Management of stable angina</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2018</a>],and the European Society of Cardiology (ECS)<em> 2016 European Guidelines on cardiovascular disease prevention in clinical practice</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2016</a>].</p><!-- end field bb84f230-c7f7-470a-ada3-a7810088fe81 --><!-- end item a0b8f2ff-1ff4-4864-8a45-a7810088fe81 --></div></section></section><section aria-labelledby="which-antiplatelet-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="which-antiplatelet-treatment">Which antiplatelet treatment should I prescribe for secondary prevention of cardiovascular disease?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5bda44fb-0bea-4fd2-a3e9-a781008a055d --><!-- begin field afd8ccb1-461f-4029-bb21-a781008a0690 --><ul><li><strong>Angina</strong><ul><li>Consider prescribing aspirin 75 mg daily for people with stable angina, taking into account the risk of bleeding and comorbidities.</li><li>Offer aspirin 75 mg as soon as possible to all people with unstable anginaand continue indefinitely, unless contraindicated by bleeding risk or aspirin hypersensitivity.<ul><li>For people in whom aspirin is contraindicated or not tolerated, consider clopidogrel 75 mg daily.</li></ul></li></ul></li><li><strong>Atrial fibrillation (AF)</strong><ul><li>Dual antiplatelettherapy (DAPT) of aspirin 75 mg daily and clopidogrel 75 mg daily may be suitable for people who are unable or unwilling to take anticoagulants. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../atrial-fibrillation/index.html">Atrial fibrillation</a>.</li></ul></li><li><strong>Acute coronary syndrome (ACS)</strong>which is medically managed (unstable angina, non-ST segment elevation myocardial infarction [NSTEMI] or ST-segment elevation myocardial infarction [STEMI]).<ul><li><strong>Prescribe DAPT</strong> aspirin 75 mg dailyplus ticagrelor 90mg twice a day for 12 months.<ul><li>Ticagrelor is the preferred choice (evenin those previously treated with clopidogrel) unless the bleeding risk outweighs the benefit.</li></ul></li><li>For people at high risk of bleeding, continue DAPTfor at least one month.</li><li>For people with MIat high ischaemic riskwho have tolerated DAPT without a bleeding complication, consider treatment with DAPT (ticagrelor 60 mg twice daily) in addition to aspirin for longer than 12 months and up to 36 months.<ul><li>If ticagrelor is not suitable, consider clopidogrel 75 mg daily (as well as aspirin) for longer than 12 months.</li></ul></li></ul></li><li><strong>Percutaneous coronary intervention (PCI)</strong>.<ul><li><strong>For people with ACS who are undergoing PCI</strong>, aspirin (75100mg) in combination with one of the following antiplatelets is initiated in secondary care:<ul><li>Prasugrel 10mg daily (or 5mg daily if the person weighs less than 60kg, or if the person is 75years of age or older).</li><li>Ticagrelor 90mg twice a day.</li><li>Clopidogrel 75mg daily (if prasugrel or ticagrelor are not suitable).</li></ul></li><li>This treatment is usually continued for up to 12months after the procedure, then aspirin is continued alone.<ul><li>For people at high risk of bleeding complications, stop DAPT after 6 months and continueaspirin alone. Prasugrel is not recommended.</li><li>For people who have tolerated DAPT without a bleeding complication, consider continuingDAPT for longer than 12 months, up to 36 months. Ticagrelor 60 mg twice daily is the preferred option.</li></ul></li><li><strong>For people with stable coronary artery disease who are undergoing PCI</strong>, aspirin 75 mg dailywith clopidogrel 75 mg daily is initiatedin secondary care and continued for 6 months.<ul><li>Ticagrelor, or prasugrelmay be considered instead of clopidogrel where appropriate.</li><li>For people at high risk of bleeding, continue DAPT for 3 months.</li><li>For people in whom 3 months of DAPT poses safety concerns, consider stopping DAPTafter 1 month.</li><li>For people who have tolerated DAPT without a bleeding complication, consider continuingDAPT for longerthan 6 months, up to36months.</li></ul></li></ul></li><li><strong>Coronary artery bypass grafting (CABG)  in people undergoing CABG antiplatelet treatment will be managed by specialists.</strong><ul><li>People treated with DAPT who then undergo CABG should continue DAPT whenit is safe to do so after surgery, and continue until the recommended duration of therapy is complete.</li></ul></li><li><strong>Stroke, ortransient ischaemic attack (TIA)</strong><ul><li>Clopidogrel 75mg dailyis the preferred antiplatelet medication.</li><li>If clopidogrel is contraindicated or not tolerated, give modifiedrelease dipyridamole (200mg twice a day) combined with low dose aspirin.</li><li>If both clopidogrel and modified-release dipyridamole are contraindicated or not tolerated, give aspirin alone.</li><li>If both clopidogrel and aspirin are contraindicated or not tolerated, give modified-release dipyridamole alone.</li><li><strong>Note: </strong>Prasugrel should not be given to people with a history of stroke or TIA.</li></ul></li><li><strong>Peripheral arterial disease (PAD), or multivasculardisease</strong><ul><li>Clopidogrel 75mg daily is the preferred antiplatelet medication.</li><li>If clopidogrel is contraindicated or not tolerated, give low dose aspirin alone.</li></ul></li></ul><!-- end field afd8ccb1-461f-4029-bb21-a781008a0690 --><!-- end item 5bda44fb-0bea-4fd2-a3e9-a781008a055d --></div><section aria-labelledby="basis-for-recommendation-938" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-938">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9387e7c6-ff6f-4ead-92b9-a781008a0695 --><!-- begin field 5f99c9db-2d3a-405c-afac-a781008a0695 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines<em>Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2010a</a>],<em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013b</a>],<em>Unstable angina and NSTEMI: early management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013a</a>], <em>Atrial fibrillation: management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014a</a>],NICE technology appraisals<em>Ticagrelor for preventing atherothrombotic events after myocardial infarction</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>], and<em>Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014b</a>], the NICE evidence summary<em>Transient ischaemic attack: clopidogrel</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2013c</a>],theScottish Intercollegiate Guidelines Network (SIGN) guidelines<em>Risk estimation and the prevention of cardiovascular disease </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2017</a>], <em>Prevention of stroke in patients with atrial fibrillation</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2014</a>],and <em>Management of stable angina </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2018</a>],the Royal College of Physicians (RCP)<em>National clinical guideline for stroke</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">RCP, 2016</a>], the European Society of Cardiology (ESC) <em>2016 European Guidelines on cardiovascular disease prevention in clinical practice</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2016</a>], the<em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>],<em>2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018b</a>], theCanadian Cardiovascular Society (CCS) guideline <em>2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">CCS, 2018</a>],the American Heart Association (AHA) and American College of Cardiology (ACC) <em>2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">AHA, 2017</a>],and the Summary of Product Characteristics for aspirin [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017a</a>],clopidogrel [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>],prasugrel [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017b</a>],and ticagrelor [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017c</a>].</p><h5>Antiplatelet therapy in atrial fibrillation (AF)</h5><ul><li>Antiplatelet therapy should only be considered for people with AF whenwarfarin or one of the newer anticoagulants has been declined [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2014</a>].</li><li>Aspirin monotherapy should notbe used solely for stroke prevention in people with AF [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014a</a>].</li><li>Clopidogrel is licensed for use in combination with aspirinfor people with AF in whom anticoagulants are unsuitable [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>]. </li></ul><h5>Clopidogrel use in transient ischaemic attack (TIA) and stroke</h5><ul><li>Aspirin plus modified-release dipyridamole and clopidogrel monotherapy are equally effective, with both options superior to aspirin monotherapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCP, 2016</a>].</li><li>NICE recommends clopidogrel as the most cost-effective antiplatelet for secondary prevention of stoke [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2010a</a>],however,clopidogrel is not licensed for use after a TIA[<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>],soNICE recommendstreatment with modified-release dipyridamole plus aspirin as the preferred treatment option for TIA [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2010a</a>].</li><li>However,the RCP considers that a unified approach to the treatment of TIA and ischaemic stroke is more appropriate and recommends clopidogrel as the preferred option for people who have had a TIA, as the benefits of using it first-line outweigh the disadvantages [<a class="bibliography-reference internal-reference" href="../../references/index.html">RCP, 2016</a>].</li><li>ESC recommendsaspirin alone, dipyridamole plus aspirin, or clopidogrel alone for people with non-cardioembolic ischaemic stroke or TIA[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2016</a>].</li></ul><h5>Low dose aspirin </h5><ul><li>The optimal dose range of aspirin in people treated with dual antiplatelet therapy (DAPT) that provides maximal protection from ischaemic events and minimizes bleeding risk appears to be 75100 mg [<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>].</li><li>People taking prasugrel should also take aspirin 75-325 mg daily [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014b</a>].</li><li>Ticagrelor should always be given with aspirin 75-100 mg [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016b</a>].</li></ul><h5>Prasugrel and high risk of bleeding</h5><ul><li>ESC does not recommend the use of prasugrel inpeople at high risk of bleeding who have undergone percutaneous coronary intervention (PCI)<strong></strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>].</li><li>The use of prasugrelin peopleat increased risk of bleeding should only be considered when the benefits in terms of prevention of ischaemic events are deemed to outweigh the risk of serious bleeding[<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017b</a>].</li></ul><h5>Duration of treatment after PCI </h5><ul><li>ESC recommends that DAPTcanbe continued for up to 30 months in people with stablecoronary artery diseasethat have undergone PCI, and that for people with ACS who undergo PCI, treatment can be continued beyond 12 months, but does not specify a maximum duration of treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>]. </li><li>However, aCanadian guideline recommends that it in both scenarios, DAPT can be continued for up to 36 months [<a class="bibliography-reference internal-reference" href="../../references/index.html">CCS, 2018</a>].</li><li>CKS recommends using clinical judgement to determine the appropriate duration of DAPT taking into account the potential benefitsandthe individual's risk of bleeding.</li></ul><!-- end field 5f99c9db-2d3a-405c-afac-a781008a0695 --><!-- end item 9387e7c6-ff6f-4ead-92b9-a781008a0695 --></div></section></section><section aria-labelledby="preventing-dyspepsia" class="ChapterBody-module--wrapper--2HCfk "><h3 id="preventing-dyspepsia">How can I help prevent dyspepsia?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9e89d085-43ef-4858-b5c4-a781008a2a75 --><!-- begin field a7c5e577-8d53-4caf-9ed3-a781008a2b84 --><ul><li>If the person is taking a dose of aspirin higher than 75 mg daily, reduce the dose to 75 mg daily (unless a higher dose is indicated) to be taken after food.<ul><li>Do not prescribe enteric coated aspirin.</li></ul></li><li>Provide general advice to help reduce gastrointestinal (GI) adverse effects. For more information, see the section on <a class="topic-reference external-reference" href="../../../dyspepsia-unidentified-cause/management/dyspepsia-unidentified-cause/index.html#initial-management">Initial management</a>in the CKS topic on <a class="topic-reference external-reference" href="../../../dyspepsia-unidentified-cause/index.html">Dyspepsia - unidentified cause</a>.</li><li>Consider testing for and treating <em>Helicobacter pylori</em> if the person has a history of ulcer disease or upper GI bleeding, unless previously tested and treated for this.</li><li><strong>If the person has a <a class="topic-reference internal-reference" href="index.html#high-risk-of-gi-adverse-effects">high risk</a> of GIadverse effects (for example, bleeding) and is taking: </strong><ul><li><strong>Low-dose aspirin alone, or in combination with ticagrelor or prasugrel:</strong><ul><li>Co-prescribe a proton pump inhibitor (PPI), such as lansoprazole, omeprazole, or pantoprazole, for gastroprotection.</li><li>For more information, see the section on <a class="topic-reference external-reference" href="../../../nsaids-prescribing-issues/management/nsaids-prescribing-issues/index.html#proton-pump-inhibitor-doses-for-gastroprotection">Licensed doses of proton pump inhibitors used for gastroprotection for people who require continued NSAID treatment</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../nsaids-prescribing-issues/index.html">NSAIDs - prescribing issues</a>.</li></ul></li><li><strong>Clopidogrel alone, or in combination with low-dose aspirin:</strong><ul><li>Co-prescribe a PPI, except omeprazole or esomeprazole.</li></ul></li></ul></li></ul><!-- end field a7c5e577-8d53-4caf-9ed3-a781008a2b84 --><!-- end item 9e89d085-43ef-4858-b5c4-a781008a2a75 --></div><section aria-labelledby="high-risk-of-gi-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h4 id="high-risk-of-gi-adverse-effects">People at high risk of GI adverse effects</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c425681f-7d45-49fa-a29c-a781008c37f1 --><!-- begin field 08750d15-001a-4e62-b1f6-a781008c38de --><ul><li><strong>People are at high risk of gastrointestinal (GI) adverse effects with antiplatelet treatment if the following risk factors are present:</strong><ul><li>High dose of aspirin.</li><li>Older age, especially aged over 70 years.</li><li>History of gastroduodenal ulcer, GI bleeding, or gastroduodenal perforation.</li><li><em>Helicobacter pylori</em> infection.</li><li>Concomitant use of medicines that are known to increase the risk of GI bleeds.</li></ul></li></ul><p><strong>Table 1.</strong> Examples of common medicines known to cause GI bleeding or ulceration.</p><table><thead><tr><th>Therapy Group</th><th>Examples</th></tr></thead><tbody><tr><td>Antiplatelets</td><td>Aspirin, clopidogrel, prasugrel</td></tr><tr><td>Antidepressants  selective serotonin-reuptake inhibitors (SSRIs)</td><td>Citalopram, fluoxetine, paroxetine</td></tr><tr><td>Anticoagulants</td><td>Warfarin, dabigatran, apixaban, rivaroxaban</td></tr><tr><td>Corticosteroids</td><td>Prednisolone</td></tr><tr><td>Nonsteroidal anti-inflammatory drugs (NSAIDs)</td><td>Aspirin, ibuprofen, diclofenac, naproxen, indometacin</td></tr><tr><td>Potassium-channel activator</td><td>Nicorandil</td></tr><tr><td colspan="2"> Nicorandil is associated with a risk of gastrointestinal ulceration, including perianal ulceration. Ulcers that result from nicorandil are refractory to treatment, including surgery; they respond only to withdrawal of nicorandil.</td></tr><tr><td colspan="2"><strong>Data from:</strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2016</a>]</td></tr></tbody></table><!-- end field 08750d15-001a-4e62-b1f6-a781008c38de --><!-- end item c425681f-7d45-49fa-a29c-a781008c37f1 --></div></section><section aria-labelledby="basis-for-recommendation-1c6" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-1c6">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1c6296a1-c337-4630-9edd-a781008a2b8d --><!-- begin field b1e07a80-5764-427b-b0cc-a781008a2b8d --><p>This information isbased on the Scottish Intercollegiate Guidelines Network (SIGN) guideline<em>Antithrombotics: indications and management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>], the European Society of Cardiology (ESC)<em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>], the American College of Cardiology Foundationconsensus document <em>Reducing g</em><em>astrointestinal</em><em>risks of antiplatelet therapy and NSAID use</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Bhatt et al, 2008</a>], the American College of Chest Physicians guideline <em>Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Eikelboom et al, 2012</a>],theNational Institute for Health and Care Excellence (NICE) guidelines <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014c</a>], Public Health England (PHE) quick reference guide<em>Test and treat for Helicobacter pylori (HP) in dyspepsia </em>recommends <em>H pylori </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2017</a>], and expert opinion in narrative reviews<em>Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas and Scheiman, 2007</a>], and<em>Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas, 2015</a>].</p><h5>Low dose aspirin </h5><ul><li>There is evidence that thegastrointestinal (GI)adverse effects of aspirin are dose-dependent. Doses of less than 300 mg daily are associated with fewer GI adverse effects than 1,200 mg daily, and doses of 100 mg or less are associated with even fewer adverse effects[<a class="bibliography-reference internal-reference" href="../../references/index.html">Eikelboom et al, 2012</a>].</li><li>To minimise the risk of bleeding, the lowest recommended dose of aspirin should be used for the clinical indication [<a class="bibliography-reference internal-reference" href="../../references/index.html">SIGN, 2013</a>].<ul><li>The standard dose of aspirin for thromboprophylaxis is 75 mg daily.</li></ul></li><li>In peopletreated with dual antiplatelet therapy (DAPT), a daily aspirin dose of 75100 mg is recommended [<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>].</li></ul><h5>Enteric-coated aspirin </h5><ul><li>Enteric-coated aspirindoes not reduce the risk ofGI complications, as the main effect of aspirin on the gastric mucosa depends on the systemic effects rather than the local topical effects [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas, 2015</a>].</li></ul><h5>Testing for <em>H. pylori</em> infection</h5><ul><li><em>H. pylori</em> infection is associated with an increased risk of duodenal damage in people taking low dose aspirin, and eradication of <em>H. pylori</em> in people with GI ulcers or bleeding is associated with a reduction in the occurrence of upper GI complications, both in non-aspirin and aspirin users [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas and Scheiman, 2007</a>].</li><li>In people taking low dose aspirinwithout ahistory of peptic ulcer, the role of <em>H. pylori</em> eradication is controversial and few data are available [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas, 2015</a>].</li><li>The Public Health England quick reference guide<em>Test and treat for Helicobacter pylori (HP) in dyspepsia </em>recommends <em>H. pylori </em>testing for peoplewith a history of gastric or duodenal ulcer/bleed who have not previously been tested, and for peoplebefore taking NSAIDsif they have a prior history of gastro-duodenal ulcers/bleeds[<a class="bibliography-reference internal-reference" href="../../references/index.html">PHE, 2017</a>].</li><li>Testing for and eradicating <em>H. pylori</em> in peoplewith a history of ulcer disease is recommended before starting chronic antiplatelet therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bhatt et al, 2008</a>].</li></ul><h5>Use of PPIs with antiplatelets </h5><ul><li>GI haemorrhage is the most common serious bleeding complication from the use of long-term antiplatelet therapy. Randomized controlled trials (RCTs) have shown that proton pump inhibitors(PPIs) reducethe rate of recurrent Gl bleeding in high-risk peoplereceiving aspirin[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>].<ul><li>There are no RCTs comparing use versusnon-use of PPIs in peopletaking aspirin plusprasugrel, or aspirin plus ticagrelor. However, the risk of GI bleeding is higher in people taking prasugrelor ticagreloras part of DAPT, compared to clopidogrel.</li></ul></li><li>PPIs are the preferred option to reduce GI adverse effects in people taking low dose aspirin, as the level of suppression provided by traditional doses of H2-receptor antagonists does not prevent NSAID related ulcers [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bhatt et al, 2008</a>].</li><li>PPIs are more effective than H2-receptor antagonists as gastroprotective agents in people taking antiplatelets [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas, 2015</a>].</li><li>Clopidogrel should not be used alone as an alternative to low dose aspirin, or low dose aspirin plus PPI in people with high risk of GI adverse effects risk to reduce the risk of GI bleeding[<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas, 2015</a>] [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bhatt et al, 2008</a>].</li></ul><h5>Choice of PPI </h5><ul><li>A possible interaction between clopidogrel and PPIs, particularly omeprazole and esomeprazole, may lead to reduced antiplatelet effects when taken concurrently [<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>].<ul><li>Pantoprazole and rabeprazole have the lowest effect.</li><li>No significant interaction occurs when PPIs are taken concurrently with prasugrel or ticagrelor.</li></ul></li><li>Consider PPIs other than omeprazole or esomeprazole in patients who are taking clopidogrel. Other Gl therapy such as H2 blockers (except cimetidine) or antacids may be more suitable in some people[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2010</a>].</li></ul><h5>PPI doses</h5><ul><li>Higher daily doses of PPIs lead to greater levels of acid suppression, however, data do not supportthe need for more than standard once-daily dosing of PPIs for people taking low dose aspirin [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bhatt et al, 2008</a>].</li></ul><h5>Risk factors for GI adverse effects</h5><ul><li>Severe comorbidities may also be a risk factor for GI adverse effects in people taking antiplatelets, however, the evidence for this is conflicting [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanas, 2015</a>]. </li></ul><!-- end field b1e07a80-5764-427b-b0cc-a781008a2b8d --><!-- end item 1c6296a1-c337-4630-9edd-a781008a2b8d --></div></section></section><section aria-labelledby="managing-antiplatelet-induced-dyspepsia" class="ChapterBody-module--wrapper--2HCfk "><h3 id="managing-antiplatelet-induced-dyspepsia">How should I manage antiplatelet-induced dyspepsia?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 16035f85-00fe-4c4f-bb56-a781008a56c1 --><!-- begin field eaa7b7a4-9530-4595-a1b4-a781008a57a8 --><ul><li><strong>In people with alarm features, refer urgently</strong><strong>using a suspected cancer pathway referral (for an appointment within 2 weeks).</strong><ul><li>For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../gastrointestinal-tract-upper-cancers-recognition-referral/index.html">Gastrointestinal tract (upper) cancers - recognition and referral</a>.</li><li>While waiting for endoscopy, consider stopping antiplatelet treatment if appropriate, or prescribe a simple antacid to relieve dyspepsia (as proton pump inhibitors [PPIs] and H2-receptor antagonists should be avoided for at least 2 weeks before endoscopy).<ul><li>Do not stop antiplatelet treatment for people at very high cardiovascular risk without seeking specialist advice (for example, after an episode of acute coronary syndrome or stroke/transient ischaemic attack, or after a percutaneous coronary intervention).</li></ul></li></ul></li><li><strong>In people without alarm features:</strong><ul><li>Ensure that general measuresto reduce the risk of gastrointestinal (GI) adverse effects have been taken. Formore information, see the CKS topic on <a class="topic-reference external-reference" href="../../../dyspepsia-unidentified-cause/index.html">Dyspepsia - unidentified cause</a>.</li><li>Prescribe an antacid or an alginate to use 'as required' for relief of dyspeptic symptoms.</li><li>If taking low-dose aspirin consider treatment with a full-dose PPIfor 1month or test and treat for<em>Helicobacter pylori</em>(if the person's status is unknown).<ul><li>For information on testing for and treating<em>H. pylori</em>as well as prescribing PPIs, see the CKS topic on <a class="topic-reference external-reference" href="../../../dyspepsia-unidentified-cause/index.html">Dyspepsia - unidentified cause</a>.</li></ul></li><li>If symptoms recur after PPI treatment or eradication treatment, prescribe the lowest dose of PPI to control symptoms.</li><li>Review maintenance treatment at least annually.</li></ul></li><li><strong>If taking clopidogrel alone or in combination with aspirin:</strong><ul><li>Avoid co-prescribing omeprazole or esomeprazole with clopidogrel use an alternative PPI,orconsider prescribing an H2-receptor antagonist (H2RA) for 1month (for example, ranitidine [avoid cimetidine]).</li></ul></li><li><strong>Refer</strong>to secondary care for investigation if symptoms persist despite treatment.</li></ul><!-- end field eaa7b7a4-9530-4595-a1b4-a781008a57a8 --><!-- end item 16035f85-00fe-4c4f-bb56-a781008a56c1 --></div><section aria-labelledby="basis-for-recommendation-78f" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-78f">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 78fcf485-9612-435e-ae33-a781008a57a8 --><!-- begin field 7391f042-634d-4cd6-8543-a781008a57a8 --><p>CKScould find no guidelines on managing dyspepsia in people taking antiplatelet medication. These recommendations are extrapolated from theNational Institute for Health and CareExcellence (NICE) guideline<em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014c</a>], and what CKS considers good clinical practice.</p><h5>Basis for testing for and treating <em>Helicobacter pylori</em></h5><ul><li>Although testing for and eradicating<em>H pylori</em>in people with a history of ulcer disease is recommended before starting long-term antiplatelet treatment, CKS identified no guidelines on the role of<em>H.pylori</em>eradicationin managing dyspepsia in people receiving low-dose aspirin.</li><li><em>H. pylori</em>infection is an important and independent risk factor for ulcer and gastrointestinal bleeding in people taking low dose aspirin [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bhatt et al, 2008</a>].</li></ul><!-- end field 7391f042-634d-4cd6-8543-a781008a57a8 --><!-- end item 78fcf485-9612-435e-ae33-a781008a57a8 --></div></section></section><section aria-labelledby="switching-antiplatelets" class="ChapterBody-module--wrapper--2HCfk "><h3 id="switching-antiplatelets">How should I manage switching of antiplatelet treatments?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 639f60b5-5e08-48a0-a378-a8f8008a14fc --><!-- begin field 22d61229-389f-499e-a374-a8f8008a1d92 --><ul><li>Switchingbetween antiplatelet medication may be required, if the currenttreatment is unsuitable.</li><li>If switching from clopidogrel to:<ul><li>Ticagrelor  start 90 mg twice daily, 24 hours after the last clopidogrel dose.</li><li>Prasugrel  start 10 mg daily, 24 hours after last clopidogrel dose.</li></ul></li><li>If switchingfrom prasugrel to:<ul><li>Clopidogrel  start 75 mg daily, 24 hours after the last prasugrel dose.</li><li>Ticagrelor start 90 mg twice daily, 24 hours after the last prasugrel dose.</li></ul></li><li>If switching from ticagrelor to:<ul><li>Clopidogrel  give a loading dose of 600 mg, 24 hours after the last ticagrelor dose. Then continue with 75 mg daily.</li><li>Prasugrel  give a 60 mg loading dose, 24 hours after the last ticagrelor dose. Then continue with 10 mg daily.</li></ul></li></ul><!-- end field 22d61229-389f-499e-a374-a8f8008a1d92 --><!-- end item 639f60b5-5e08-48a0-a378-a8f8008a14fc --></div><section aria-labelledby="basis-for-recommendation-9ff" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-9ff">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9ff4f7b5-26b6-4e9b-8fbc-a8f8008a1e2c --><!-- begin field 7eaba05b-a931-4755-b97c-a8f8008a1e2c --><p>These recommendations are based on the European Society of Cardiology (ESC) guideline <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>].</p><!-- end field 7eaba05b-a931-4755-b97c-a8f8008a1e2c --><!-- end item 9ff4f7b5-26b6-4e9b-8fbc-a8f8008a1e2c --></div></section></section><section aria-labelledby="surgery-dental-treatment" class="ChapterBody-module--wrapper--2HCfk "><h3 id="surgery-dental-treatment">How should I manage people taking antiplatelets who are undergoing surgery ordental treatment?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 78a27cf2-1965-4396-aad0-a8f8008ab676 --><!-- begin field b712d258-fc45-4b2d-ba91-a8f8008ab842 --><ul><li>Advise people taking antiplatelet medicationsto inform dentists or medical teamsbefore any surgery is scheduled.</li><li>Dual antiplatelet therapy (DAPT) increases the risk of surgical bleeding complications.<ul><li>The bleeding risk is further increased if ticagrelor or prasugrel are used rather thanclopidogrel.</li></ul></li><li>For people undergoing dental surgery antiplatelet therapy should continue uninterrupted.</li><li>For people undergoing coronary artery bypass grafting (CABG), discontinue:<ul><li>Ticagrelor 37 days before surgery.</li><li>Clopidogrel57 days before surgery.</li><li>Prasugrel at least 7 days before surgery.</li></ul></li><li>For people undergoing non-cardiac surgery,the risk of bleeding and thrombosisshould be considered bythe specialist team.</li></ul><!-- end field b712d258-fc45-4b2d-ba91-a8f8008ab842 --><!-- end item 78a27cf2-1965-4396-aad0-a8f8008ab676 --></div><section aria-labelledby="basis-for-recommendation-7b8" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-7b8">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7b8e2555-52bc-45fb-9b16-a8f8008ab856 --><!-- begin field fe54695e-3d15-4e8d-bfc0-a8f8008ab856 --><p>These recommendations are based on the European Society of Cardiology (ESC) <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>], theScottish Dental Clinical Effectiveness Programme (SDCEP)<em>Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">SDCEP, 2015</a>],and the Summary of Product Characteristics forclopidogrel [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>],ticagrelor [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017c</a>] and prasugrel [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017b</a>].</p><ul><li>Continuation of dual antiplatlet therapyuntil coronary artery bypass grafting (CABG) increases the risk of excessive perioperative bleeding, transfusions, and re-exploration for bleeding. It is recommended that clopidogrel, ticagreloror prasugrelare discontinued whenever possible before elective CABG [<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>].</li><li>The SPCs recommend that antiplatelets should be discontinued 7 days before surgery if antiplatlet effect is not desired [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017c</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2017b</a>].</li><li>However, ESC advises that for people undergoing CABG, the followingdiscontinuation timings should be considered [<a class="bibliography-reference internal-reference" href="../../references/index.html">ESC, 2018a</a>]:<ul><li>Ticagrelor  3 days before surgery.</li><li>Clopidogrel  5 days before surgery.</li><li>Prasugrel  at least 7 days before surgery.</li></ul></li></ul><!-- end field fe54695e-3d15-4e8d-bfc0-a8f8008ab856 --><!-- end item 7b8e2555-52bc-45fb-9b16-a8f8008ab856 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI"><!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>